Biopharmaceutical company AbbVie had a strong year, with revenues growing nearly 23%. Sales for the company’s top-performing immune defense drugs continued to rise in 2021, especially domestically, where revenues for the best-selling Humira drug increased by 7.6%. Humira did not perform as well on the global market, where it was edged out by biosimilar competition, but international revenues for products including plaque psoriasis treatment Skyrizi and rheumatoid arthritis drug Rinvoq rose by several billion dollars each. AbbVie predicted strong growth in 2022 with an increased focus on expanding its products’ coverage in both American and European markets.
Smith Collection—Getty Images
Company Information
As of 8/3/2022
Country
U.S.
Headquarters
North Chicago, Ill.
Industry
Pharmaceuticals
CEO
Richard A. Gonzalez
Website
Company Type
Public
Ticker
ABBV
Revenues ($M)
$56,197
Profits ($M)
$11,542
Market Value ($M)
$264,607
Employees
50,000
Market value as of July 19, 2022.
Key Financials (Last Fiscal Year)
$ millions
% change
Revenues ($M)
$56,197
22.7%
Profits ($M)
$11,542
150%
Assets ($M)
$146,529
-
Total Stockholder Equity ($M)
$15,408
-
Profit Ratios
Profit as % of Revenues
20.5%
Profits as % of Assets
7.9%
Profits as % of Stockholder Equity
74.9%
Earnings Per Share (Last Fiscal Year)
Earnings Per Share ($)
645
EPS % Change (from 2020)
137.1%
EPS % Change (5 year annual rate)
12.2%
EPS % Change (10 year annual rate)
-
Total Return
Total Return to Investors (2021)
32.2%
Total Return to Investors (5 year, annualized)
22%
Total Return to Investors (10 year, annualized)
-
AbbVie Rank History
Historical Data
| Year | Revenues ($M) | Profits ($M) | Assets ($M) | Total Stockholder Equity ($M) |
|---|---|---|---|---|
| 2021 | $45,80437.7% | $4,616-41.4% | $150,565 | $13,076 |
| 2020 | $33,2661.6% | $7,88238.6% | $89,115 | $-8,172 |
| 2019 | $32,75316.1% | $5,6877.1% | $59,352 | $-8,446 |
| 2018 | $28,21610.1% | $5,309-10.8% | $70,786 | $5,097 |
| 2017 | $25,63812.2% | $5,95315.7% | $66,099 | $4,636 |
SHOW MORE
Lists ranking AbbVie
